Physitrack PLC (STO:PTRK)
| Market Cap | 130.09M -42.2% |
| Revenue (ttm) | 149.47M +2.2% |
| Net Income | -92.13M |
| EPS | -5.70 |
| Shares Out | 16.26M |
| PE Ratio | n/a |
| Forward PE | 28.92 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 16,523 |
| Open | 8.22 |
| Previous Close | 8.00 |
| Day's Range | 8.00 - 8.22 |
| 52-Week Range | 7.56 - 21.70 |
| Beta | 0.57 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 21, 2026 |
About Physitrack
Physitrack PLC, together with its subsidiaries, provides digital healthcare solutions in the United Kingdom, Europe, North America, and internationally. It operates through two segments, Lifecare and Wellness. The company offers Physitrack, a remote therapeutic monitoring platform that provides a suite of tools for exercise program prescription, patient-reported adherence and tracking, and telehealth for private practices, occupational health and case management, healthcare systems and hospitals, and sports. It also offers Physiapp, a mobile ap... [Read more]
Financial Performance
In 2025, Physitrack's revenue was 13.52 million, a decrease of -2.50% compared to the previous year's 13.87 million. Losses were -8.71 million, 34.9% more than in 2024.
Financial numbers in EUR Financial StatementsNews
Physitrack Earnings Call Transcript: Q1 2026
Achieved profitability in Q1 2026 with strong recurring revenue and robust margins. Strategic focus on North America and RTM launch positions the business for accelerated growth, with margin recovery and share buyback program expected in H2 2026.
Physitrack Quarterly report: Q1 2026
Physitrack has published its Q1 2026 quarterly earnings report on April 23, 2026.
Physitrack Slides: Q1 2026
Physitrack has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 23, 2026.
Physitrack Earnings Call Transcript: Q4 2025
2025 saw a strategic shift to profitability, with adjusted EBITDA margin rising to 35% and free cash flow turning positive. Lifecare drove stable growth, while Wellness was restructured for higher margins. North America is a key focus for future expansion.
Physitrack Annual report: Q4 2025
Physitrack has published its Q4 2025 annual report on February 27, 2026.
Physitrack Quarterly report: Q4 2025
Physitrack has published its Q4 2025 quarterly earnings report on February 27, 2026.
Physitrack Slides: Q4 2025
Physitrack has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 27, 2026.
Physitrack Earnings Call Transcript: Q3 2025
Q3 2025 saw strong profitability, with free cash flow up 200% year-on-year and SaaS revenue at 88% of total. Lifecare drove growth with high margins, while Wellness was streamlined for future scalability. ARR is expected to stabilize and return to growth in 2026.
Physitrack Quarterly report: Q3 2025
Physitrack has published its Q3 2025 quarterly earnings report on October 21, 2025.
Physitrack Slides: Q3 2025
Physitrack has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 21, 2025.
Physitrack Earnings Call Transcript: Q2 2025
Q2 saw a historic swing to positive cash flow and margin expansion, driven by a shift to 87% recurring revenue and strong Lifecare performance. Wellness SaaS ARR surged 109% year-over-year, and the group is targeting doubled revenue and 40-45% EBITDA margins in the medium term.
Physitrack Quarterly report: Q2 2025
Physitrack has published its Q2 2025 quarterly earnings report on July 24, 2025.
Physitrack Slides: Q2 2025
Physitrack has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on July 24, 2025.